380237-42-3

Upstream product

• 108-24-7 acetic anhydride 
• 220648-78-2 tert-butyl-(4-(N’-hydroxycarbamimidoyl)benzyl)carbamate 
• 66389-80-8 tert-butyl N-[(4-cyanophenyl)methyl]carbamate 
• 10406-25-4 4-aminobenzyl cyanide 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 380237-43-4 4-(acetyloxamidino)benzylamine hydrochloride 
• 217313-82-1 tert-butyl (4-carbamimidoylbenzyl)carbamate acetate salt 
• 162696-15-3 N-Boc-4-aminomethyl benzamidine 
• 380237-44-5 C₁₇H₂₄N₄O₅ 
• 600707-97-9 C₁₀H₁₃N₃O₂ 

Relevant academic research and scientific papers

Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof

The invention relates to the novel base-substituted benzylamine analogs of general formula (I), wherein A represents P2-P1 with P1=(A) and P2=(B), for use as coagulation factor Xa inhibitors. The invention also relates to the production and use of said analogs in the therapy and prophylaxis of cardiovascular diseases and thromboembolic events.

4-Amidinobenzylamine-Based Inhibitors of Urokinase

A series of 4-amidinobenzylamine-based peptidomimetic inhibitors of urokinase was synthesized. The most potent one, benzylsulfonyl-D-Ser-Ala-4-amidinobenzylamide 16, inhibits uPA with a Ki of 7.7 nM but is less selective than 10 with a Gly as P2 residue. Hydroxyamidine and carbonate prodrugs were prepared, which are rapidly converted into the active inhibitors in rats after subcutaneous application.